Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 4/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 2/20 | 0.37 |
| ▸ | DNM1L | O00429 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723723 | 0.95 | OGA (0.48) | ACKR3OGATYRDNM1LHSD11B1 | |
| SCHEMBL5723813 | 0.95 | OGA (0.46) | ACKR3OGATYRDNM1LHSD11B1 | |
| SCHEMBL5724338 | 0.94 | OGA (0.49) | ACKR3OGATYRDNM1LHSD11B1 | |
| SCHEMBL5724215 | 0.88 | OGA (0.42) | ACKR3OGAL3MBTL1 | |
| SCHEMBL5724038 | 0.84 | PARP1 (0.38) | ACKR3OGAL3MBTL1 | |
| SCHEMBL5724230 | 0.84 | OGA (0.46) | ACKR3OGAL3MBTL1 | |
| SCHEMBL5724330 | 0.83 | ACKR3 (0.46) | ACKR3OGATYRTNKSDNM1L | |
| SCHEMBL5724059 | 0.82 | HRH3 (0.44) | ACKR3OGA | |
| SCHEMBL5723749 | 0.81 | TDP1 (0.48) | DNM1LL3MBTL1 | |
| SCHEMBL5724125 | 0.80 | OGA (0.42) | ACKR3OGAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | ACKR3 4262/4885OGA 3469/4885TYR 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.